Radiosurgery + TTFields for Lung Cancer
Trial Summary
What is the purpose of this trial?
The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 inoperable brain metastasis or 2-10 brain metastases, treated with NovoTTF-200M and supportive treatment compared to supportive treatment alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Research Team
Manmeet Ahluwalia, MD
Principal Investigator
Cleveland Clinic, Cleveland OH USA
Paul Brown, MD
Principal Investigator
MD Anderson Cancer Center, Houston TX USA
Minesh Mehta, MD
Principal Investigator
Miami Cancer Institute, Miami FL USA
Vinai Gondi, MD
Principal Investigator
Northwestern Medicine Cancer Center, Warenville IL USA
Eligibility Criteria
This trial is for adults with a new diagnosis of 1 inoperable brain metastasis or 2-10 brain lesions from NSCLC, confirmed by MRI. Participants must have a life expectancy of at least 3 months, be able to use the NovoTTF-200M device independently or with help, and not be part of other trials involving brain therapy.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- NovoTTF-100M device (Device)
- NovoTTF-200M device (Device)
Find a Clinic Near You
Who Is Running the Clinical Trial?
NovoCure GmbH
Lead Sponsor